Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박영요 | * |
dc.contributor.author | 정우식 | * |
dc.contributor.author | 윤하나 | * |
dc.contributor.author | 변영준 | * |
dc.date.accessioned | 2016-08-28T11:08:17Z | - |
dc.date.available | 2016-08-28T11:08:17Z | - |
dc.date.issued | 2010 | * |
dc.identifier.issn | 2005-6737 | * |
dc.identifier.other | OAK-13443 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/229440 | - |
dc.description.abstract | Purpose: We aimed to determine the treatment of choice criteria for benign prostatic hyperplasia (BPH) by analyzing the factors causing alpha-adrenergic receptor blocker (α-blocker) monotherapy failure. Materials and Methods: This retrospective study enrolled 129 patients with BPH who were prescribed an α-blocker. Patients were allocated to a transurethral resection of prostate (TURP) group (after having at least a 6-month duration of medication) and an α-blocker group. We compared the differences between the two groups for their initial prostate volume, serum prostate-specific antigen (PSA), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and postvoid residual urine volume (PVR). Results: Of the 129 patients, 54 were in the TURP group and 75 were in the α-blocker group. Statistically significant differences (p<0.05) between the two groups were found in the prostate volume (50.8 ml vs. 34.4 ml), PSA (6.8 ng/ml vs. 3.6 ng/ml), Qmax (6.84 ml/sec vs. 9.99 ml/sec), and IPSS (27.3 vs. 16.8). According to the multiple regression analysis, the significant factors in ?-blocker monotherapy failure were the IPSS (p <0.001) and prostate volume (p=0.015). According to the receiver operating characteristic (ROC) curve-based prediction regarding surgical treatment, the best cutoff value for the prostate volume and IPSS were 35.65 ml (sensitivity 0.722, specificity 0.667) and 23.5 (sensitivity 0.852, specificity 0.840), respectively. Conclusions: At the initial diagnosis of BPH, patients with a larger prostate volume and severe IPSS have a higher risk of ?-blocker monotherapy failure. In this case, combined therapy with 5-alpha-reductase inhibitor (5-ARI) or surgical treatment may be useful. © The Korean Urological Association, 2010. | * |
dc.language | English | * |
dc.title | Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia | * |
dc.type | Article | * |
dc.relation.issue | 7 | * |
dc.relation.volume | 51 | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 488 | * |
dc.relation.lastpage | 491 | * |
dc.relation.journaltitle | Korean Journal of Urology | * |
dc.identifier.doi | 10.4111/kju.2010.51.7.488 | * |
dc.identifier.scopusid | 2-s2.0-77954982582 | * |
dc.author.google | Hong K.P. | * |
dc.author.google | Byun Y.J. | * |
dc.author.google | Yoon H. | * |
dc.author.google | Park Y.Y. | * |
dc.author.google | Chung W.S. | * |
dc.contributor.scopusid | 박영요(8286581200) | * |
dc.contributor.scopusid | 정우식(56012331800;35914993800) | * |
dc.contributor.scopusid | 윤하나(8723844200) | * |
dc.contributor.scopusid | 변영준(27167947000) | * |
dc.date.modifydate | 20240118161124 | * |